novavax
appoints
leadership
team
advance
nanoflu
regulatory
licensure
team
focus
global
nanoflu
licensure
evaluation
influenza
combination
vaccine
russell
rip
wilson
promoted
executive
vice
president
nanoflu
general
manager
gaithersburg
globe
newswire
novavax
nasdaq
nvax
novavax
nasdaq
nvax
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
formation
leadership
team
advance
nanoflu
regulatory
licensure
promotion
russell
rip
wilson
executive
vice
president
role
general
manager
wilson
focus
exclusively
leading
efforts
advance
nanoflu
company
influenza
vaccine
candidate
global
licensure
well
exploration
combined
influenza
vaccine
could
used
setting
novavax
announced
results
successful
nanoflu
pivotal
phase
clinical
trial
earlier
year
intends
seek
regulatory
approval
food
drug
administration
fda
accelerated
approval
pathway
previously
granted
company
formation
dedicated
team
enables
novavax
accelerate
activities
required
file
biologics
licensing
application
bla
nanoflu
parallel
extensive
development
manufacturing
work
underway
vaccine
candidate
said
stanley
erck
president
chief
executive
officer
full
confidence
rip
team
brought
nanoflu
inception
successful
phase
testing
excited
potential
develop
combined
influenza
vaccine
use
wilson
joined
novavax
recently
responsible
global
business
development
quality
program
management
functions
across
company
entire
pipeline
new
role
lead
team
work
closely
broader
novavax
team
obtain
licensure
nanoflu
fda
global
authorities
well
evaluate
development
pentavalent
nanoflu
vaccine
currently
available
flu
vaccines
provide
inconsistent
inadequate
protection
seasonal
influenza
said
wilson
nanoflu
already
completed
pivotal
phase
clinical
trial
achieved
primary
endpoints
excited
potential
provide
important
vaccine
option
patients
need
older
adult
population
committed
leading
team
licensure
strong
sense
new
nanoflu
leadership
team
includes
several
novavax
veterans
led
successful
development
vaccine
completion
successful
pivotal
phase
clinical
trial
team
also
recently
completed
key
activities
related
development
addition
wilson
team
comprised
following
leaders
tim
hahn
senior
vice
president
cmc
nanoflu
led
cmc
activities
nanoflu
since
beginning
program
recently
hahn
led
establishment
global
supply
chain
novavax
adjuvant
key
component
nanoflu
vaccines
vivek
shinde
vice
president
clinical
development
nanoflu
served
clinical
lead
nanoflu
program
since
inception
phase
shinde
also
recently
led
initiation
phase
clinical
trial
south
africa
new
team
establish
separate
nanoflu
development
unit
within
novavax
building
company
established
knowledge
base
discovery
development
innovative
vaccines
prevent
serious
infectious
diseases
team
also
benefit
joint
shared
services
key
departments
within
novavax
nanoflu
recombinant
hemagglutinin
ha
protein
nanoparticle
influenza
vaccine
produced
novavax
insect
cell
baculovirus
system
nanoflu
uses
ha
amino
acid
protein
sequences
recommended
circulating
virus
ha
sequences
nanoflu
contains
novavax
patented
adjuvant
vaccine
candidate
engineered
genetic
sequence
virus
causes
disease
created
using
novavax
recombinant
nanoparticle
technology
generate
antigen
derived
coronavirus
spike
protein
contains
novavax
patented
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
contains
purified
protein
antigen
replicate
cause
preclinical
trials
demonstrated
induction
antibodies
block
binding
spike
protein
receptors
targeted
virus
critical
aspect
effective
vaccine
protection
phase
portion
phase
clinical
trial
generally
elicited
robust
antibody
responses
numerically
superior
seen
human
convalescent
sera
also
evaluated
phase
trial
uk
two
ongoing
phase
studies
began
august
phase
trial
south
africa
phase
continuation
australia
novavax
secured
billion
funding
global
coronavirus
vaccine
program
including
million
funding
coalition
epidemic
preparedness
innovations
cepi
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
undertaking
clinical
trials
vaccine
candidate
virus
causes
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
vaccine
candidates
incorporate
novavax
proprietary
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
novavax
statements
statements
herein
relating
future
novavax
ongoing
development
vaccine
adjuvant
products
statements
novavax
cautions
statements
subject
numerous
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
risks
uncertainties
include
identified
heading
risk
factors
novavax
annual
report
form
year
ended
december
quarterly
report
form
period
ended
june
filed
securities
exchange
commission
sec
caution
investors
place
considerable
reliance
statements
contained
press
release
encouraged
read
filings
sec
available
discussion
risks
uncertainties
statements
press
release
speak
date
document
undertake
obligation
update
revise
statements
business
subject
substantial
risks
uncertainties
including
referenced
investors
potential
investors
others
give
careful
consideration
risks
uncertainties
contacts
investors
erika
trahan
ir
media
brandzone
kogs
communication
edna
kaplan
kaplan
